Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Louvet, C.
Right arrow Articles by de Gramont, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Louvet, C.
Right arrow Articles by de Gramont, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 6 (March), 2002: 1512-1518
© 2002 American Society for Clinical Oncology

Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study

By C. Louvet, T. André, G. Lledo, P. Hammel, H. Bleiberg, C. Bouleuc, E. Gamelin, M. Flesch, E. Cvitkovic, A. de Gramont

From Service d’Oncologie-Médecine Interne, Hôpital Saint-Antoine, Service d’Oncologie, Hôpital Tenon, and GERCOR, Paris; Clinique St Jean, Lyon; Service de Gastro-Entérologie, Hôpital Beaujon, Clichy; Service d’Oncologie, Hôpital d’Argenteuil, Argenteuil; Service d’Oncologie, Centre Paul Papin, Angers; Fondation Drevon, Dijon; and Cvitkovic Associés Consultants, Kremlin-Bicêtre, France; and Institut Jules Bordet, Brussels, Belgium.

Address reprint requests to Christophe Louvet, MD, Service d’Oncologie, Médecine Interne, Hôpital Saint-Antoine, 184 Rue du Faubourg Saint-Antoine, 75571 Paris, Cedex 12, France; email: christophe.louvet{at}sat.ap-ap-hop-paris.fr

PURPOSE: Based on preclinical in vitro synergy data, this study evaluated the activity and toxicity of a gemcitabine/oxaliplatin combination in patients with metastatic and locally advanced pancreatic adenocarcinoma.

PATIENTS AND METHODS: Previously untreated metastatic and locally advanced unresectable pancreatic adenocarcinoma patients were enrolled onto this multicenter phase II study. Patients received gemcitabine 1,000 mg/m2 as a 10-mg/m2/min infusion on day 1 and oxaliplatin 100 mg/m2 as a 2-hour infusion on day 2 every 2 weeks. Patients with metastatic disease were treated until evidence of progressive disease, whereas patients with locally advanced disease received six cycles in the absence of progression, followed when appropriate by concomitant radiochemotherapy.

RESULTS: Among 64 eligible patients included in eight centers, 30 had locally advanced and 34 had metastatic disease. Response rate for the 62 patients with measurable disease was 30.6% (95% confidence interval, 19.7% to 42.3%), 31.0% for locally advanced and 30.3% for metastatic patients. Among 58 assessable patients, 40% had clinical benefit. Median progression-free survival and median overall survival (OS) were 5.3 and 9.2 months, respectively, with 36% of patients alive at 1 year. Median OS for patients with metastatic disease and locally advanced disease were 8.7 and 11.5 months, respectively. With 574 treatment cycles (median per patient, nine; range, zero to 27), grade 3/4 toxicity per patient was 11% for neutropenia and thrombocytopenia, 14% for nausea or vomiting, 6.2% for diarrhea, and 11% for peripheral neuropathy, with no toxic deaths.

CONCLUSION: Palliative effects, response rate, and survival observed with this well-tolerated gemcitabine/oxaliplatin combination deserve additional evaluation. A comparative study of combination therapy versus gemcitabine alone is ongoing.

Preliminary results presented at the Thirty-Seventh Annual Meeting of the American Society of Clinical Oncology, May 12-15, 2001, San Francisco, CA.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Hunsberger, Y. Zhao, and R. Simon
A Comparison of Phase II Study Strategies
Clin. Cancer Res., October 1, 2009; 15(19): 5950 - 5955.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Laurent, E. Monsaert, T. Boterberg, A. Demols, I. Borbath, M. Polus, A. Hendlisz, B. de Hemptinne, C. Mahin, P. Scalliet, et al.
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study
Ann. Onc., August 1, 2009; 20(8): 1369 - 1374.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. R. Vora, H. Zheng, Z. K. Stadler, C. S. Fuchs, and A. X. Zhu
Serum {alpha}-Fetoprotein Response as a Surrogate for Clinical Outcome in Patients Receiving Systemic Therapy for Advanced Hepatocellular Carcinoma
Oncologist, July 1, 2009; 14(7): 717 - 725.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. J. Chua and J. R. Zalcberg
Pancreatic cancer--is the wall crumbling?
Ann. Onc., July 1, 2008; 19(7): 1224 - 1230.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Moureau-Zabotto, J.-M. Phelip, P. Afchain, L. Mineur, T. Andre, V. Vendrely, G. Lledo, O. Dupuis, F. Huguet, E. Touboul, et al.
Concomitant Administration of Weekly Oxaliplatin, Fluorouracil Continuous Infusion, and Radiotherapy After 2 Months of Gemcitabine and Oxaliplatin Induction in Patients With Locally Advanced Pancreatic Cancer: A Groupe Coordinateur Multidisciplinaire en Oncologie Phase II Study
J. Clin. Oncol., March 1, 2008; 26(7): 1080 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. H. Kulke, L. S. Blaszkowsky, D. P. Ryan, J. W. Clark, J. A. Meyerhardt, A. X. Zhu, P. C. Enzinger, E. L. Kwak, A. Muzikansky, C. Lawrence, et al.
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
J. Clin. Oncol., October 20, 2007; 25(30): 4787 - 4792.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
V. Heinemann, R. Labianca, A. Hinke, and C. Louvet
Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study
Ann. Onc., October 1, 2007; 18(10): 1652 - 1659.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T El Gnaoui, J Dupuis, K Belhadj, J-P Jais, A Rahmouni, C Copie-Bergman, I Gaillard, M Divine, I Tabah-Fisch, F Reyes, et al.
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
Ann. Onc., August 1, 2007; 18(8): 1363 - 1368.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Welch and M. J. Moore
Combination Chemotherapy in Advanced Pancreatic Cancer: Time to Raise the White Flag?
J. Clin. Oncol., June 1, 2007; 25(16): 2159 - 2161.
[Full Text] [PDF]

Home page
 JCOHome page
F. Huguet, T. Andre, P. Hammel, P. Artru, J. Balosso, F. Selle, E. Deniaud-Alexandre, P. Ruszniewski, E. Touboul, R. Labianca, et al.
Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies
J. Clin. Oncol., January 20, 2007; 25(3): 326 - 331.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. R. Cardenes, E. G. Chiorean, J. DeWitt, M. Schmidt, and P. Loehrer
Locally advanced pancreatic cancer: current therapeutic approach.
Oncologist, June 1, 2006; 11(6): 612 - 623.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Lecomte, B. Landi, P. Beaune, P. Laurent-Puig, and M.-A. Loriot
Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy.
Clin. Cancer Res., May 15, 2006; 12(10): 3050 - 3056.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. X. Zhu, L. S. Blaszkowsky, D. P. Ryan, J. W. Clark, A. Muzikansky, K. Horgan, S. Sheehan, K. E. Hale, P. C. Enzinger, P. Bhargava, et al.
Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
J. Clin. Oncol., April 20, 2006; 24(12): 1898 - 1903.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. H. Ko, E. Dito, B. Schillinger, A. P. Venook, E. K. Bergsland, and M. A. Tempero
Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas
J. Clin. Oncol., January 20, 2006; 24(3): 379 - 385.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. S. P. Rocha Lima and A. M. Flores
Gemcitabine Doublets in Advanced Pancreatic Cancer: Should We Move On?
J. Clin. Oncol., January 20, 2006; 24(3): 327 - 329.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. van der Heijden, J. R. Brody, D. A. Dezentje, E. Gallmeier, S. C. Cunningham, M. J. Swartz, A. M. DeMarzo, G. J. A. Offerhaus, W. H. Isacoff, R. H. Hruban, et al.
In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor
Clin. Cancer Res., October 15, 2005; 11(20): 7508 - 7515.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Louvet, R. Labianca, P. Hammel, G. Lledo, M.G. Zampino, T. Andre, A. Zaniboni, M. Ducreux, E. Aitini, J. Taieb, et al.
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
J. Clin. Oncol., May 20, 2005; 23(15): 3509 - 3516.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Conroy, B. Paillot, E. Francois, R. Bugat, J.-H. Jacob, U. Stein, S. Nasca, J.-P. Metges, O. Rixe, P. Michel, et al.
Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer--A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer Study
J. Clin. Oncol., February 20, 2005; 23(6): 1228 - 1236.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Thongprasert, S. Napapan, C. Charoentum, and S. Moonprakan
Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma
Ann. Onc., February 1, 2005; 16(2): 279 - 281.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Ducreux, E. Mitry, M. Ould-Kaci, V. Boige, J. F. Seitz, R. Bugat, J. L. Breau, O. Bouche, P. L. Etienne, J. M. Tigaud, et al.
Response to the letter "Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU and infusional 5-FU alone in advanced pancreatic carcinoma patients", by C. Allior (Ann. Oncol 2004; 15: 1576-1577)
Ann. Onc., October 1, 2004; 15(10): 1577 - 1578.
[Full Text] [PDF]

Home page
 Ann OncolHome page
T. Andre, C. Tournigand, O. Rosmorduc, S. Provent, F. Maindrault-Goebel, D. Avenin, F. Selle, F. Paye, L. Hannoun, S. Houry, et al.
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study
Ann. Onc., September 1, 2004; 15(9): 1339 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Ducreux, E. Mitry, M. Ould-Kaci, V. Boige, J. F. Seitz, R. Bugat, J. L. Breau, O. Bouche, P. L. Etienne, J. M. Tigaud, et al.
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients
Ann. Onc., March 1, 2004; 15(3): 467 - 473.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Goel, A. Bulgaru, H. Hochster, S. Wadler, W. Zamboni, M. Egorin, P. Ivy, L. Leibes, F. Muggia, G. Lockwood, et al.
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors
Ann. Onc., November 1, 2003; 14(11): 1682 - 1687.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B.F. El-Rayes, M.M. Zalupski, A.F. Shields, U. Vaishampayan, L.K. Heilbrun, V. Jain, V. Adsay, J. Day, and P.A. Philip
Phase II Study of Gemcitabine, Cisplatin, and Infusional Fluorouracil in Advanced Pancreatic Cancer
J. Clin. Oncol., August 1, 2003; 21(15): 2920 - 2925.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. D. Petty, M. C. Nicolson, S. Skaria, T. S. Sinclair, L. M. Samuel, and M. Koruth
A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity
Ann. Onc., July 1, 2003; 14(7): 1100 - 1105.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. P. Neoptolemos, D. Cunningham, H. Friess, C. Bassi, D. D. Stocken, D. M. Tait, J. A. Dunn, C. Dervenis, F. Lacaine, H. Hickey, et al.
Adjuvant therapy in pancreatic cancer: historical and current perspectives
Ann. Onc., May 1, 2003; 14(5): 675 - 692.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Kralidis, S. Aebi, H. Friess, M. W. Buchler, and M. M. Borner
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer
Ann. Onc., April 1, 2003; 14(4): 574 - 579.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. R. Alberts, P. M. Townley, R. M. Goldberg, S. S. Cha, D. J. Sargent, D. F. Moore, J. E. Krook, H. C. Pitot, T. R. Fitch, M. Wiesenfeld, et al.
Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study
Ann. Onc., April 1, 2003; 14(4): 580 - 585.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. McKenna and M. Eatock
The Medical Management of Pancreatic Cancer: A Review
Oncologist, April 1, 2003; 8(2): 149 - 160.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Mavroudis, P. Pappas, C. Kouroussis, S. Kakolyris, S. Agelaki, K. Kalbakis, N. Androulakis, J. Souglakos, N. Vardakis, M. Nikolaidou, et al.
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors
Ann. Onc., February 1, 2003; 14(2): 304 - 312.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Louvet, T. Andre, J.M. Tigaud, E. Gamelin, J.Y. Douillard, R. Brunet, E. Francois, J.H. Jacob, D. Levoir, A. Taamma, et al.
Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients
J. Clin. Oncol., December 1, 2002; 20(23): 4543 - 4548.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Rao and D. Cunningham
Advanced pancreatic cancer--5 years on
Ann. Onc., August 1, 2002; 13(8): 1165 - 1168.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online